专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4322984A1 PSG1 FOR USE IN THE TREATMENT OF OSTEOARTHRITIS 审中-实审
公开(公告)号：EP4322984A1
公开(公告)日：2024-02-21
申请号：EP22720463.3
申请日：2022-04-14
申请人： University College Cork-National University of Ireland Cork
发明人： MOORE, Tom , CLOVER, Anthony James Peterson
IPC分类号： A61K38/17 , A61P19/02 , A61P17/02 , A61K39/00

2. 发明授权

EP2365997B1 A PROCESS FOR PREPARING SILICA MICROPARTICLES 有权
公开(公告)号：EP2365997B1
公开(公告)日：2019-03-20
申请号：EP09764593.1
申请日：2009-11-26
申请人： University College Cork - National University of Ireland, Cork
发明人： GLENNON, Jeremy D. , OMAMOGHO, Jesse
IPC分类号： C09C1/30 , B01J20/283 , B01J20/286 , B01J20/32 , C01B33/18

3. 发明公开

EP3422006A1 DETECTION OF RISK OF PRE-ECLAMPSIA 有权
公开(公告)号：EP3422006A1
公开(公告)日：2019-01-02
申请号：EP18157264.5
申请日：2010-12-21
申请人： University College Cork, National University of Ireland, Cork
发明人： KENNY, Louise , NEWTON BAKER, Philip , BROADHURST, David
IPC分类号： G01N33/68
摘要： A method for the early prediction of risk of hypertensive disorders in pregnant women, including for example eclampsia, mild pre-eclampsia, chronic hypertension, EPH gestosis, gestational hypertension, superimposed pre-eclampsia, HELLP syndrome, or nephropathy.

4. 发明公开

EP3077516A1 GENETIC TRANSFORMATION OF BIFIDOBACTERIA 有权转让
标题翻译：遗传转化双歧杆菌
公开(公告)号：EP3077516A1
公开(公告)日：2016-10-12
申请号：EP13840184.9
申请日：2013-12-02
申请人： Compagnie Gervais Danone , University College Cork, National University of Ireland Cork
发明人： VAN SINDEREN, Douwe , O'CONNELL MOTHERWAY, Mary , WATSON, Debbie , SMOKVINA, Tamara , GARAULT, Peggy
IPC分类号： C12N15/74 , C12N1/20
CPC分类号： C12N15/746 , C12N1/20 , C12N9/1007 , C12Y201/01
摘要： The present invention concerns a method for genetically transforming a Bifidobacterium strain comprising a step of methylation of a shuttle vector in an E. coli or a Gram-positive bacterium strain by two type II DNA methyltransferases from a Bifidobacterium: a methyltransferase enzyme that methylates the adenine base at position 4 of the nucleotide sequence RTCAGG and a methyltransferase enzyme that methylates the cytosine base at position 4 of the nucleotide sequence GGWCC. The present invention also concerns genetic tools and culture media useful for carrying out said method.
摘要翻译：本发明涉及用于遗传转化双歧杆菌菌株的方法，其包括通过来自双歧杆菌的两种II型DNA甲基转移酶在大肠杆菌或革兰氏阳性菌株中甲基化穿梭载体的步骤：使腺嘌呤甲基化的甲基转移酶核苷酸序列RTCAGG的第4位的碱基和甲基化核苷酸序列GGWCC的第4位的胞嘧啶碱基的甲基转移酶。本发明还涉及可用于实施所述方法的遗传工具和培养基。

5. 发明公开

EP3047861A3 INTRACORONARY INFUSION OF IGF-1 FOR MYOCARDIAL REPAIR 有权
标题翻译： IGF1 ZUR MYKARDIALEN REPARATUR
公开(公告)号：EP3047861A3
公开(公告)日：2016-08-31
申请号：EP16152830.2
申请日：2009-11-27
申请人： University College Cork-National University of Ireland, Cork
发明人： Caplice, Noel
IPC分类号： A61L29/04 , A61L29/16
CPC分类号： A61L29/048 , A61L29/16 , A61L2300/414 , A61L2300/602
摘要： Provided herein are methods for treating an individual having (suffering from) an acute myocardial infarction and drug eluting stents useful for treating such individuals. These methods include treating an individual by introducing, such as by surgically inserting, at a site of an acute coronary artery occlusion upstream of the site of acute myocardial infarction, a drug eluting stent (DES) that is capable of eluting from 25pg to 950pg of IGF-1 directly into the coronary circulation. The treatment is specifically directed to stimulation of repair or survival of damaged cardiac muscle or left ventricular remodeling.
摘要翻译：本文提供了治疗患有（患有）急性心肌梗死的个体和用于治疗这些个体的药物洗脱支架的个体的方法。这些方法包括通过例如通过手术插入在急性心肌梗塞部位上游的急性冠状动脉闭塞部位的药物洗脱支架（DES）进行治疗，该药物洗脱支架能够从25pg-950pg IGF-1直接进入冠状动脉循环。该治疗特别针对刺激受损的心肌或左心室重塑的修复或存活。

6. 发明公开

EP3056562A1 INDUCED SMOOTH MUSCLE-TYPE CELLS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF IN CELL-BASED TISSUE REGENERATION AND TREATMENT OF VASCULAR OCCLUSION 审中-公开
标题翻译：诱导的平滑肌，方法其制造及其使用单元格基于组织再生和冠状动脉治疗
公开(公告)号：EP3056562A1
公开(公告)日：2016-08-17
申请号：EP16155308.6
申请日：2016-02-11
申请人： University College Cork-National University of Ireland, Cork
发明人： Caplice, Noel
IPC分类号： C12N5/071
CPC分类号： C12N5/0691 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2501/604 , C12N2510/00
摘要： An induced smooth muscle-like cell (iSMC) is described. The iSMC is prepared by reprogramming a primitive progenitor cell comprising introducing into the cell an agent capable of increasing the expression of myocardin in the primitive progenitor cell. The agent may be a nucleic acid construct comprising a KLF4 knockdown agent, an artificial myocardinspecific transactivator, or a myocardin transgene typically under the control of a transcriptional promotor. Methods of producing the cells, and the use of the cells in autologous tissue regeneration therapy or treatment of vascular occlusion in humans is also described.
摘要翻译：的诱导的平滑肌细胞样细胞（ISMC）进行说明。该ISMC通过重编程原始祖细胞，其包含导入细胞增加在祖细胞心肌素的表达能够原始的试剂制备。所述试剂可以是核酸构建体，包含KLF4敲低剂，人工反myocardinspecific活化剂，或一个转录启动子的控制下，典型地，转基因心肌素。由此描述生产细胞，并且使用在自体组织再生治疗或在人类中治疗血管闭塞的细胞的方法。

7. 发明公开

EP3047861A2 INTRACORONARY INFUSION OF IGF-1 FOR MYOCARDIAL REPAIR 有权
标题翻译： IGF-1在心脏修复中的应用
公开(公告)号：EP3047861A2
公开(公告)日：2016-07-27
申请号：EP16152830.2
申请日：2009-11-27
申请人： University College Cork-National University of Ireland, Cork
发明人： Caplice, Noel
IPC分类号： A61L29/04 , A61L29/16
CPC分类号： A61L29/048 , A61L29/16 , A61L2300/414 , A61L2300/602
摘要： Provided herein are methods for treating an individual having (suffering from) an acute myocardial infarction and drug eluting stents useful for treating such individuals. These methods include treating an individual by introducing, such as by surgically inserting, at a site of an acute coronary artery occlusion upstream of the site of acute myocardial infarction, a drug eluting stent (DES) that is capable of eluting from 25pg to 950pg of IGF-1 directly into the coronary circulation. The treatment is specifically directed to stimulation of repair or survival of damaged cardiac muscle or left ventricular remodeling.
摘要翻译：本文提供了用于治疗患有（患有）急性心肌梗塞的个体和用于治疗此类个体的药物洗脱支架的方法。这些方法包括通过例如通过手术插入在急性心肌梗塞部位上游的急性冠状动脉闭塞部位引入能够从25pg至950pg的药物洗脱支架（DES）洗脱的药物洗脱支架（DES） IGF-1直接进入冠脉循环。该治疗具体针对刺激受损心肌或左心室重构的修复或存活。

8. 发明公开

EP2941299A1 A THORACOSCOPIC ELECTROPORATION DEVICE WITH A SUCTION HEAD AND WITH NEEDLE ELECTRODES 失效
标题翻译：用吸头，针与铅电胸腔镜
公开(公告)号：EP2941299A1
公开(公告)日：2015-11-11
申请号：EP13811540.7
申请日：2013-12-19
申请人： University College Cork-National University of Ireland, Cork
发明人： SODEN, Declan , HINCHION, John
IPC分类号： A61N1/32 , A61B18/14
CPC分类号： A61N1/325 , A61B17/00234 , A61B18/1482 , A61B2017/00292 , A61B2017/00809 , A61B2017/00867 , A61B2017/308 , A61B2018/00291 , A61B2018/00541 , A61B2018/00613 , A61B2018/143 , A61B2018/1475 , A61N1/0502 , A61N1/327
摘要： A thoracoscopic electroporation device for carrying out electroporation on tissue includes a suction head and a plurality of needle electrodes. The needle electrodes include a central needle providing a first electrode and a plurality of second needles which are spaced-apart around the periphery of the suction head. The electrodes are movable from a retracted configuration to a deployed configuration and in the deployed configuration the needles extend from the suction head. The suction head has a retracted delivery configuration and an expanded deployed configuration. The suction head includes a suitable flexible material for biasing the suction head into the expanded deployed configuration. The suction head has channels for the needles and the needles are movable through the channels from the retracted to the deployed configuration. In the deployed configuration, the central first needle extends beyond the peripheral needles.

9. 发明公开

EP2760883A1 ACCUMULATION OF METABOLIC PRODUCTS IN BACTERIAL MICROCOMPARTMENTS 审中-公开
标题翻译：巴克斯坦薄荷酮中的阿萨姆门多芬
公开(公告)号：EP2760883A1
公开(公告)日：2014-08-06
申请号：EP12777872.8
申请日：2012-09-27
申请人： University College Cork, National University of Ireland Cork , University of Kent
发明人： PRENTICE, Michael , WARREN, Martin , LIANG, Mingzhi
IPC分类号： C07K14/195 , C12N1/20 , A23L1/30 , A61K35/74 , C02F3/30 , C12N9/12
CPC分类号： C12P3/00 , A23L33/135 , A61K38/45 , C07K14/195 , C12N1/20 , C12N9/1229 , C12N15/70 , C12P21/00 , C12Y207/04001 , Y02A50/473
摘要： A non-therapeutic method of accumulating a polymeric or high molecular weight molecular product within a bacterial microcompartment in bacterial cytoplasm, which method employs a recombinant bacteria which is genetically engineered to express a microcompartment containing an enzyme capable of converting a low molecular weight substrate into a polymeric or high molecular weight product, the method comprising the steps of: incubating the recombinant bacteria with the low-molecular weight substrate, or a precursor of the low molecular weight substrate which is capable of being metabolised to the substrate within the recombinant bacteria, such that the substrate or precursor is taken up by the bacteria, wherein the substrate enters the microcompartment and the enzyme within the microcompartment converts the substrate to a polymeric or high molecular weight molecular product, and wherein the polymeric or high molecular weight molecular product is accumulated within the microcompartment due to its size.
摘要翻译：在细菌细胞质中在细菌微室内积聚聚合物或高分子量分子产物的非治疗方法，该方法使用重组细菌，其被遗传工程化以表达含有能够将低分子量底物转化为聚合物或高分子量产物，该方法包括以下步骤：将重组细菌与低分子量底物或低分子量底物的前体一起孵育，该前体能够被代谢至重组细菌内的底物，如底物或前体被细菌吸收，其中基质进入微室，微室内的酶将底物转化为聚合物或高分子量分子产物，并且其中聚合或高分子量分子产物积聚在微型房间到期到它的大小。

10. 发明公开

EP2560357A1 Analysis of calls recorded at a call centre for selecting calls for agent evaluation 审中-公开
标题翻译：评估，在呼叫中心捕获，来电，来评估操作人员选择呼叫
公开(公告)号：EP2560357A1
公开(公告)日：2013-02-20
申请号：EP11177610.0
申请日：2011-08-15
申请人： University College Cork-National University of Ireland, Cork
发明人： Curran, Dara , Sutton, Kevin
IPC分类号： H04M3/51
CPC分类号： G06F17/30746 , H04M3/42221 , H04M3/5175
摘要： This invention relates to a method and system for selecting a call centre agent's call for evaluation. Presently, calls are selected at random for evaluation by the call centre team leader. Generally speaking, this is an inefficient way to choose the calls, is time consuming and can result in an unfair evaluation of the agent's performance. According to the present invention there is provided a method and system for selecting an agent's calls for evaluation which entails analysing each of the calls, extracting certain call audio features and using the extracted features to score the calls based on the call's features. Once the calls have been scored, they are clustered into groups of similarly-featured calls. In this way, calls that are typical and atypical of an agent's performance may be retrieved more reliably and faster than was heretofore the case. According to one particularly preferred embodiment, a selection of calls suitable for evaluation can be presented to the call centre team leader.
摘要翻译：本发明涉及一种用于选择呼叫中心座席的呼叫进行评估的方法和系统。目前，呼叫随机由呼叫中心团队领导选择进行评估。一般来说，这是选择电话方式效率极低，非常耗时，而且可以在代理人的业绩不公平的评价结果英寸。根据本发明，提供了用于选择代理的评价这需要实现分析每个呼叫，提取某些呼叫的音频特征并使用所提取的特征的得分基于呼叫的功能的呼叫的呼叫的方法和系统。一旦通话havebeen进球，他们都聚集到类似功能的通话组。通过这种方式，电话确实是典型的和非典型的代理的性能可能会更可靠地检索和比迄今的情况下更快。。根据一个特别优选实施方案，选择适合于评价的呼叫可被呈现给呼叫中心组长。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式